Articles

Human Papillomavirus (HPV) remains one of the most common viral infections worldwide and is strongly associated with cervical cancer. While preventive HPV vaccines have transformed public health strategies, effective treatment options for existing HPV infections and precancerous cervical lesions continue to be an active area of research.

About Authors
Harsh Bhardwaj1, Muskan Baller2, Rupali Dilip Taru3, Raaz K Maheshwari4

About Authors
Harsh Bardwaj¹*, Monika CHamoli2, Raaz K Maheshwari3
Assistant Professor, Department of Chemistry, Shri Ratanlal Kanwarlal Patni Girls’ College, Kishangarh, Ajmer, Rajasthan, India

Harsh Bhardwaj1*, Sakshi Jain2, Raaz K Maheshwari3
1Assistant Professor, Department of Chemistry, Shri RK Patni Girls’ College, Kishangarh, Ajmer, Rajasthan, India

In the 1970s, India was facing a silent epidemic of cataract blindness. Millions of elderly people were losing their eyesight, not because treatment was unavailable, but because it was unaffordable. Cataract surgery required replacing the cloudy natural lens with a clear artificial intraocular lens (IOL). At that time, these lenses were imported and cost nearly 100 US dollars each, far beyond the reach of poor patients.

At the center of the solution was a remarkable man, Dr. Govindappa Venkataswamy, lovingly known as Dr. V.

The year 2025 marked a strong revival in pharmaceutical mergers and acquisitions, as global drug makers moved firmly to strengthen pipelines, manage upcoming patent expiries, and secure sustainable growth. Several high-value and strategically important deals defined the year, reflecting renewed confidence in the sector. Major pharmaceutical companies pursued acquisitions not just for scale, but for access to late-stage assets, innovative technologies, and high-growth therapeutic areas.

Vinay Kumar Singh. 
Head-Formulation
Kumar Organic Products Research Centre Pvt. Ltd.,
Bengaluru
Email : formulation_krc@kopresearchcentre.net